Repligen Corporation

NASDAQ RGEN

Data sourced from

and

Daily

Download Data

Repligen Corporation Price to Sales Ratio (P/S) on June 03, 2024: 13.83

Repligen Corporation Price to Sales Ratio (P/S) is 13.83 on June 03, 2024, a 17.32% change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.

Repligen Corporation 52-week high Price to Sales Ratio (P/S) is 17.44 on March 21, 2024, which is 26.10% above the current Price to Sales Ratio (P/S).
Repligen Corporation 52-week low Price to Sales Ratio (P/S) is 9.50 on October 30, 2023, which is -31.34% below the current Price to Sales Ratio (P/S).
Repligen Corporation average Price to Sales Ratio (P/S) for the last 52 weeks is 13.83.

NASDAQ: RGEN

Repligen Corporation

CEO	Mr. Anthony J. Hunt
IPO Date	March 26, 1990
Location	United States
Headquarters	Building 1, Waltham, MA, United States, 02453
Employees	1,783
Sector	Healthcare
Industry	Medical instruments & supplies

Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Key trends